Literature DB >> 15685039

Clinical results of radiation therapy for stage I esophageal cancer: a single institutional experience.

Yoshiyuki Shioyama1, Katsumasa Nakamura, Tomonari Sasaki, Saiji Ooga, Yusuke Urashima, Masahiko Kimura, Satoru Uehara, Hiromi Terashima, Hiroshi Honda.   

Abstract

From 1992 through 2001, 29 patients with stage I esophageal cancer were treated with radiation therapy. All patients had squamous cell carcinoma. Seventeen patients were treated with radiotherapy alone, and 12 were treated with a combination of chemotherapy and radiotherapy. Most of the chemotherapy regimens included cisplatin and/or 5-fluorouracil (5-FU). Twelve patients were treated with intracavitary irradiation (low-dose rate: 6, high-dose rate: 6) after external radiotherapy. Median fraction and total doses of external radiotherapy given were 2.0 Gy and 60.6 Gy, respectively. Median doses of intracavitary irradiation were 18 Gy/6 fractions in low-dose-rate brachytherapy and 13.5 Gy/4.5 fractions in high-dose-rate brachytherapy. The 5-year overall survival rate was 62%. The 5-year local control rate was 44%. Of the 29 patients, 9 had in-field recurrence in the esophagus and 1 had recurrence in the esophagus outside of the irradiated field. Of 9 patients with in-field local recurrence, 1 also developed mediastinal lymph node metastases and 1 had distant metastasis. Radiation therapy is an effective treatment modality for stage I esophageal cancer.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15685039     DOI: 10.1097/01.coc.0000139021.91718.ee

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN: 0277-3732            Impact factor:   2.339


  5 in total

1.  Recommendations of the Spanish Brachytherapy Group of SEOR for HDR endoluminal treatments. Part 1: Oesophagus.

Authors:  Á Rovirosa; J Anchuelo; V Crispin; C Gutiérrez; A Herreros; I Herruzo; J C Menéndez; P Pino; A Polo; S Rodríguez
Journal:  Clin Transl Oncol       Date:  2015-04-17       Impact factor: 3.405

2.  Radiation sensitivities of 31 human oesophageal squamous cell carcinoma cell lines.

Authors:  Sadayuki Ban; Yuichi Michikawa; Ken-ichi Ishikawa; Masashi Sagara; Koji Watanabe; Yutaka Shimada; Johji Inazawa; Takashi Imai
Journal:  Int J Exp Pathol       Date:  2005-08       Impact factor: 1.925

3.  Long-term outcomes of intraluminal brachytherapy in combination with external beam radiotherapy for superficial esophageal cancer.

Authors:  Yuji Murakami; Yasushi Nagata; Ikuno Nishibuchi; Tomoki Kimura; Masahiro Kenjo; Yuko Kaneyasu; Tomoyuki Okabe; Yasutoshi Hashimoto; Yukio Akagi
Journal:  Int J Clin Oncol       Date:  2011-07-12       Impact factor: 3.402

Review 4.  Multimodality approach for locally advanced esophageal cancer.

Authors:  Khaldoun Almhanna; Jonathan R Strosberg
Journal:  World J Gastroenterol       Date:  2012-10-28       Impact factor: 5.742

5.  Esophageal cancer practice guidelines 2017 edited by the Japan Esophageal Society: part 1.

Authors:  Yuko Kitagawa; Takashi Uno; Tsuneo Oyama; Ken Kato; Hiroyuki Kato; Hirofumi Kawakubo; Osamu Kawamura; Motoyasu Kusano; Hiroyuki Kuwano; Hiroya Takeuchi; Yasushi Toh; Yuichiro Doki; Yoshio Naomoto; Kenji Nemoto; Eisuke Booka; Hisahiro Matsubara; Tatsuya Miyazaki; Manabu Muto; Akio Yanagisawa; Masahiro Yoshida
Journal:  Esophagus       Date:  2018-08-31       Impact factor: 3.671

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.